[
  {
    "ts": null,
    "headline": "Castration-sensitive Prostate Cancer Market Projected to Grow at a 13.2% CAGR (2020-2034), Driven by Expanded Approval and Wider Commercialization Opportunity in nmCSPC Segment | DelveInsight",
    "summary": "DelveInsight's Castration-sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, CSPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].",
    "url": "https://finnhub.io/api/news?id=05b4ed31e988d179bd6de3f3f9a16e98193a5b54f2ab3736bd3308f62d87845f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767652260,
      "headline": "Castration-sensitive Prostate Cancer Market Projected to Grow at a 13.2% CAGR (2020-2034), Driven by Expanded Approval and Wider Commercialization Opportunity in nmCSPC Segment | DelveInsight",
      "id": 137997879,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "DelveInsight's Castration-sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, CSPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].",
      "url": "https://finnhub.io/api/news?id=05b4ed31e988d179bd6de3f3f9a16e98193a5b54f2ab3736bd3308f62d87845f"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Pfizer (PFE) Valuation After Recent Share Price Weakness And Dividend Support",
    "summary": "Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its past three-month return at a 4.1% decline, sharpening focus on its current valuation. See our latest analysis for Pfizer. At a share price of US$25.18, Pfizer’s 7 day and 1 day share price returns in positive territory contrast with its weaker 30 and 90 day share price returns and its 3 year total shareholder return of 38.1% decline, suggesting momentum has been fading...",
    "url": "https://finnhub.io/api/news?id=eb38a6c530acd4d333cdbf9180f983edd49d99e2b4e92eec358e267fd1f850b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767647434,
      "headline": "Assessing Pfizer (PFE) Valuation After Recent Share Price Weakness And Dividend Support",
      "id": 137997880,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its past three-month return at a 4.1% decline, sharpening focus on its current valuation. See our latest analysis for Pfizer. At a share price of US$25.18, Pfizer’s 7 day and 1 day share price returns in positive territory contrast with its weaker 30 and 90 day share price returns and its 3 year total shareholder return of 38.1% decline, suggesting momentum has been fading...",
      "url": "https://finnhub.io/api/news?id=eb38a6c530acd4d333cdbf9180f983edd49d99e2b4e92eec358e267fd1f850b1"
    }
  },
  {
    "ts": null,
    "headline": "This Flying-Under-the-Radar Pharma Stock Pays Nearly 7% (While Everyone's Sleeping)",
    "summary": "Investors seem to be underestimating this company's foreseeable future.",
    "url": "https://finnhub.io/api/news?id=d22bf1147f9b3b2edf3097f1c52af2c70a13fe4a7c4e33733ed0885b36eb5905",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767632700,
      "headline": "This Flying-Under-the-Radar Pharma Stock Pays Nearly 7% (While Everyone's Sleeping)",
      "id": 137992475,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investors seem to be underestimating this company's foreseeable future.",
      "url": "https://finnhub.io/api/news?id=d22bf1147f9b3b2edf3097f1c52af2c70a13fe4a7c4e33733ed0885b36eb5905"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New November Dividend Record - 100 Holdings With 12 Buys",
    "summary": "Read about the latest moves in my dividend stock portfolio and why I trimmed NVDA/AMD on valuation and rotated into BDCs (ARCC, OBDC, HTGC) for yield.",
    "url": "https://finnhub.io/api/news?id=c7d57cc52fce12c1c1fb6836f77982bdb9233d7d33af4280465110aaef63946d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767628048,
      "headline": "My Dividend Stock Portfolio: New November Dividend Record - 100 Holdings With 12 Buys",
      "id": 137994613,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Read about the latest moves in my dividend stock portfolio and why I trimmed NVDA/AMD on valuation and rotated into BDCs (ARCC, OBDC, HTGC) for yield.",
      "url": "https://finnhub.io/api/news?id=c7d57cc52fce12c1c1fb6836f77982bdb9233d7d33af4280465110aaef63946d"
    }
  },
  {
    "ts": null,
    "headline": "These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever",
    "summary": "With the S&P 500 trading at 26 times forward earnings, valuations are a concern entering 2026. Consider these 3 discounted stocks to insulate your portfolio.",
    "url": "https://finnhub.io/api/news?id=d0b835e432ccb57b42bb52b6fc292dcbe7d240771bed6242248b4d487487c5d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767627300,
      "headline": "These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever",
      "id": 138001947,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "With the S&P 500 trading at 26 times forward earnings, valuations are a concern entering 2026. Consider these 3 discounted stocks to insulate your portfolio.",
      "url": "https://finnhub.io/api/news?id=d0b835e432ccb57b42bb52b6fc292dcbe7d240771bed6242248b4d487487c5d3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference",
    "summary": "NEW YORK, January 05, 2026--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PST.",
    "url": "https://finnhub.io/api/news?id=2c352a67f147d88270ec0ee1b02eee374ca09745375400862c52e0fb55ff21b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767625200,
      "headline": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference",
      "id": 137991258,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, January 05, 2026--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PST.",
      "url": "https://finnhub.io/api/news?id=2c352a67f147d88270ec0ee1b02eee374ca09745375400862c52e0fb55ff21b0"
    }
  },
  {
    "ts": null,
    "headline": "Is It Time to Dump Your Shares of Eli Lilly?",
    "summary": "Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.",
    "url": "https://finnhub.io/api/news?id=6a14e106f706aa55814ec6cf8b4b6598b094364c9c0d68a3b1572eaa7a7ae725",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767622800,
      "headline": "Is It Time to Dump Your Shares of Eli Lilly?",
      "id": 137991007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.",
      "url": "https://finnhub.io/api/news?id=6a14e106f706aa55814ec6cf8b4b6598b094364c9c0d68a3b1572eaa7a7ae725"
    }
  },
  {
    "ts": null,
    "headline": "Better Dividend Stock: Ford vs. Pfizer",
    "summary": "Both Ford and Pfizer have very attractive dividend yields.",
    "url": "https://finnhub.io/api/news?id=f8d6cd70d8e7b5064d325888532e3acf2f0c011b25ee6e44e64f0c46e96f8f4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767619200,
      "headline": "Better Dividend Stock: Ford vs. Pfizer",
      "id": 137991260,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Both Ford and Pfizer have very attractive dividend yields.",
      "url": "https://finnhub.io/api/news?id=f8d6cd70d8e7b5064d325888532e3acf2f0c011b25ee6e44e64f0c46e96f8f4d"
    }
  },
  {
    "ts": null,
    "headline": "NFJ: Sacrificing Gains For Yield Could Lead To Underperformance In 2026",
    "summary": "Virtus NFJ fund analysis: 9.41% yield, covered distribution, 9.75% NAV discount, and covered-call tradeoffs amid rate-cut outlookâread now.",
    "url": "https://finnhub.io/api/news?id=ad7697ce8c5bc326483299cf95ab69c4e0065a3545f85cb1993b09fcfff041a4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767613406,
      "headline": "NFJ: Sacrificing Gains For Yield Could Lead To Underperformance In 2026",
      "id": 137992246,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2230823757/image_2230823757.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Virtus NFJ fund analysis: 9.41% yield, covered distribution, 9.75% NAV discount, and covered-call tradeoffs amid rate-cut outlookâread now.",
      "url": "https://finnhub.io/api/news?id=ad7697ce8c5bc326483299cf95ab69c4e0065a3545f85cb1993b09fcfff041a4"
    }
  },
  {
    "ts": null,
    "headline": "3 Stocks Under $50 with Questionable Fundamentals",
    "summary": "The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.",
    "url": "https://finnhub.io/api/news?id=175d8e5c9bb4df5170ac8288a1a36eae7c071759889804730563b04c62edf60f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767587777,
      "headline": "3 Stocks Under $50 with Questionable Fundamentals",
      "id": 137991261,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.",
      "url": "https://finnhub.io/api/news?id=175d8e5c9bb4df5170ac8288a1a36eae7c071759889804730563b04c62edf60f"
    }
  }
]